Swiss National Bank Decreases Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Swiss National Bank decreased its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 10.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 228,900 shares of the company’s stock after selling 25,300 shares during the period. Swiss National Bank’s holdings in MiMedx Group were worth $2,007,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of MDXG. Vanguard Group Inc. raised its stake in shares of MiMedx Group by 4.1% in the third quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock valued at $46,927,000 after buying an additional 250,812 shares during the period. Cannell Capital LLC lifted its holdings in MiMedx Group by 106.7% during the third quarter. Cannell Capital LLC now owns 2,273,762 shares of the company’s stock valued at $16,576,000 after purchasing an additional 1,173,506 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in MiMedx Group by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,076,509 shares of the company’s stock worth $7,848,000 after purchasing an additional 85,792 shares during the period. EAM Investors LLC increased its stake in shares of MiMedx Group by 20.9% in the third quarter. EAM Investors LLC now owns 664,213 shares of the company’s stock worth $4,842,000 after purchasing an additional 114,880 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of MiMedx Group by 1,577.5% in the fourth quarter. Russell Investments Group Ltd. now owns 525,059 shares of the company’s stock valued at $4,605,000 after purchasing an additional 493,759 shares during the period. 79.15% of the stock is owned by institutional investors.

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the transaction, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at approximately $3,815,674.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently commented on MDXG. StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. Lake Street Capital started coverage on MiMedx Group in a research note on Thursday, March 7th. They set a “buy” rating and a $12.00 price objective on the stock. Finally, Mizuho raised their target price on MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MiMedx Group presently has a consensus rating of “Buy” and an average target price of $12.25.

MiMedx Group Trading Down 0.3 %

MiMedx Group stock opened at $7.75 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.71 and a current ratio of 3.29. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.27. The stock has a market cap of $1.14 billion, a P/E ratio of 17.61 and a beta of 1.44. The firm’s fifty day moving average price is $7.21 and its 200-day moving average price is $7.71.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. The business had revenue of $84.71 million for the quarter, compared to analyst estimates of $79.36 million. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. Equities research analysts forecast that MiMedx Group, Inc. will post 0.34 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.